| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2014: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2012: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
Tumor necrosis factor-α（TNF-α）and its receptors (TNFR1 And TNFR2) play important roles for progression of autoimmune diseases. Therefore, they are considered to be promising drug targets for such diseases. However, differences of the function of TNFR1 and TNFR2, especially, the role of TNFR2 in diseases have not been understood well. In order to clear the possibility of the TNFR2 as a novel drug target, functions of TNFR2 must be well-investigated. This study aimed for clear the function of TNFR2 by using TNFR1/TNFR2 specific TNF mutants developed by our laboratory. Here, we identified a protein APP3 as a novel cytoplasmic adaptor molecule of TNFR2. We also found that APP3 played an important role for signal transduction from TNFR2 to JNK/MAP kinase pathway activation. These findings would be valuable for understanding the function of TNFR2.
|
